Nanomedex Overview

  • Founded
  • 2002
Founded
  • Status
  • Out of Business
  • Latest Deal Type
  • Out of Business

Nanomedex General Information

Description

Developer of a sedative-hypnotic agent designed to use in the induction and maintenance of anesthesia or sedation. The company's sedative-hypnotic agent represents an improved formulation with the same concentration of propofol as the marketed products, in a novel and proprietary oil-in-water emulsion suitable for intravenous administration, enabling chemists to minimize the concentration of propofol and result in less injection-site pain, inflammation and irritation.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
  • 8383 Greenway Boulevard
  • Suite 619
  • Middleton, WI 53562
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Nanomedex Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Out of Business 01-Aug-2018 00.00 Completed Out of Business
8. Later Stage VC 01-Jan-2011 00.00 Completed Generating Revenue
7. Grant 03-Nov-2010 00.000 00.00 Completed Generating Revenue
6. Accelerator/Incubator 01-Feb-2010 00.00 Completed Generating Revenue
5. Later Stage VC 02-Jun-2009 00000 00.00 Completed Generating Revenue
4. Later Stage VC (Series A) 01-Mar-2009 00000 00000 Completed Generating Revenue
3. Later Stage VC (Series A) 30-Aug-2008 00000 00000 Completed Generating Revenue
2. Accelerator/Incubator Completed Startup
1. Capitalization Completed Startup
To view Nanomedex’s complete valuation and funding history, request access »